VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
STLN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
STLNStarling Oncology, Inc.
$3.40$362M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSTLNFinancials

Starling Oncology, Inc. (STLN) Income Statement

7Y historyFree accessUpdated daily

Revenue growth accelerated to 34.6% YoY in Q2 2026, with gross margin improving from 12.6% in Q1 2024 to 14.7% in Q1 2026, though operating margin remains negative at -2.9%.

Income StatementBalance SheetCash FlowRatios

STLN Income Statement

Annual statement

STLN Income Statement

Starling Oncology, Inc. (STLN) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Sales/Revenue620.45M502.73M393.41M324.24M252.48M203M187.51M155.41M
Revenue Growth %--21.33%28.42%24.37%8.26%20.66%-
Cost of Goods Sold377.44M426.29M339.42M264.67M200.39M162.16M150.64M125.46M
COGS % of Revenue-84.8%86.27%81.63%79.37%79.88%80.33%80.73%
Gross Profit73.25M76.44M54M59.57M52.09M40.85M36.88M29.94M
Gross Margin %11.81%15.2%13.73%18.37%20.63%20.12%19.67%19.27%
Gross Profit Growth %---9.36%14.36%27.53%10.76%23.17%-
Operating Expenses264.03M112.52M114.11M136.59M134.04M86.71M45.07M32.59M
OpEx % of Revenue-22.38%29.01%42.13%53.09%42.71%24.04%20.97%
Selling, General & Admin118.33M105.57M000041.9M29.64M
SG&A % of Revenue-21%----22.34%19.07%
Research & Development00000000
R&D % of Revenue--------
Other Operating Expenses4M6.94M114.11M136.59M134.04M86.71M3.18M2.94M
Operating Income-21.02M-36.08M-60.12M-77.02M-81.95M-45.86M-8.2M-2.64M
Operating Margin %-3.39%-7.18%-15.28%-23.75%-32.46%-22.59%-4.37%-1.7%
Operating Income Growth %--21.94%6.02%-78.71%-459.52%-209.89%-
EBITDA-14.41M-29.14M-53.83M-71.14M-77.54M-42.52M-5.02M297.11K
EBITDA Margin %-2.32%-5.8%-13.68%-21.94%-30.71%-20.94%-2.68%0.19%
EBITDA Growth %--24.34%8.25%-82.37%-747.31%-1788.91%-
D&A (Non-Cash Add-back)6.61M6.94M6.29M5.87M4.41M3.34M3.18M2.94M
EBIT-14.08M-49.46M-57.17M-60.15M-72.01M-45.38M-14.47M-2.63M
Net Interest Income-5.71M-11.28M-7.5M-6.78M-4.08M-320K-347K-3.38K
Interest Income00000000
Interest Expense7.52M11.28M7.5M6.78M4.08M320K347K3.38K
Other Income/Expense-14.52M-24.65M-4.54M-6.09M81.86M34.26M-6.62M6.63K
Pretax Income-35.54M-60.74M-64.66M-83.1M-91K-11.6M-14.81M-2.64M
Pretax Margin %-5.73%-12.08%-16.44%-25.63%-0.04%-5.71%-7.9%-1.7%
Income Tax0-131K0-36K-243K-671K-492.82K1.38M
Effective Tax Rate %0%0.22%0%0.04%267.03%5.79%3.33%-52.43%
Net Income-35.54M-60.61M-64.66M-83.07M152K-10.93M-14.32M-4.02M
Net Margin %-5.73%-12.06%-16.44%-25.62%0.06%-5.38%-7.64%-2.59%
Net Income Growth %--22.16%-54750%101.39%23.7%-256.13%-
Net Income (Continuing)-35.54M-60.61M-64.66M-83.07M152K-10.93M-14.32M-4.02M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)-0.03-0.54-0.71-0.92-0.21-0.16-0.24-0.06
EPS Growth %--22.83%-338.1%-31.25%33.33%-284.62%-
EPS (Basic)--0.54-0.71-0.920.00-0.16-0.24-0.06
Diluted Shares Outstanding1.05B92.39M75.04M73.75M80.61M66.23M59.12M64.45M
Basic Shares Outstanding1.05B92.39M75.04M73.75M72.79M66.23M59.12M64.45M
Dividend Payout Ratio--------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Momentum Accelerates Sharply

TOI's revenue surged 34.6% year-over-year to $161.3M in 2026Q2, accelerating from 21.5% growth in 2025Q2, according to the latest quarterly report.

The sequential acceleration from 21.5% to 34.6% suggests the company is scaling its oncology care network rapidly, likely through de novo clinic openings or acquisitions. However, the sustainability of this growth is uncertain as it outpaces the broader market, and investors should monitor whether volume or pricing is the primary driver.

Gross Margin Expansion Signals Pricing Power

Gross margin improved from 12.6% in 2024Q1 to 14.7% in 2026Q1, though it dipped to 14.7% in 2026Q1 from 16.0% in 2025Q4, per financial statements.

The upward trend in gross margin from 12.6% to 14.7% over two years indicates improving cost management or better payer contracts, but the recent sequential decline suggests volatility. This margin remains thin relative to peers, implying limited pricing power in a competitive reimbursement environment.

Operating Leverage Emerging as Losses Narrow

Operating loss improved from -$18.0M in 2024Q1 to -$4.6M in 2026Q2, with operating margin rising from -19.0% to -2.9%, based on reported quarterly data.

The operating margin improvement from -19.0% to -2.9% indicates that revenue growth is outpacing fixed cost increases, demonstrating positive operating leverage. However, the company still operates at a loss, and the path to profitability depends on sustaining this leverage while managing SG&A growth.

Net Losses Fluctuate with Non-Operating Items

Net income swung from -$19.9M in 2024Q1 to -$9.8M in 2026Q2, but EPS improved 46.7% year-over-year, as per the income statement.

The wide variance in net income relative to operating income suggests significant non-operating items, such as interest expense or one-time charges, are impacting the bottom line. Stock-based compensation of $2.8M in 2026Q2 adds to dilution, but the improving EPS trend indicates the company is reducing losses per share.

SG&A Discipline Drives Margin Recovery

SG&A as a percentage of revenue fell from 24.9% in 2024Q4 to 18.5% in 2026Q2, while COGS remained the dominant cost, per the latest filings.

The reduction in SG&A intensity from 24.9% to 18.5% of revenue indicates improved overhead efficiency, which is critical for a company with thin gross margins. However, COGS still consumes over 85% of revenue, leaving little room for error in cost control.

2025Q2 Marks Turning Point in Loss Trajectory

Operating loss peaked at -$18.0M in 2024Q1, then steadily improved to -$4.6M by 2026Q2, a 74% reduction, according to quarterly income statements.

The inflection began in 2025Q2 when revenue growth accelerated past 20% and operating margin improved from -9.5% to -9.4%, signaling that scale was starting to offset fixed costs. This trend has persisted, suggesting the company may be approaching breakeven, but the durability of this improvement depends on maintaining revenue growth.

What Could Invalidate the Base Case

Despite narrowing losses, TOI's gross margin remains thin and volatile, and the company has not yet achieved profitability, raising questions about the durability of its growth.

Short-sellers might argue that the revenue acceleration is not translating into sustainable profitability, as gross margins are still below 15% and operating losses persist. The reliance on SG&A cuts to drive margin improvement may not be repeatable, and any slowdown in revenue growth could expose the lack of underlying earnings power. Additionally, the high stock-based compensation suggests dilution risks that could pressure EPS further.

STLN — Frequently Asked Questions

Quick answers to the most common questions about buying STLN stock.

What was Starling Oncology, Inc.'s (STLN) revenue in 2025?

For fiscal year 2025, Starling Oncology, Inc. (STLN) reported total revenue of $502.7M. This represents a 223.5% increase compared to $155.4M in 2019.

Is Starling Oncology, Inc. (STLN) profitable?

Starling Oncology, Inc. (STLN) reported a net loss of $60.6M for the fiscal year ending 2025.

What is Starling Oncology, Inc.'s operating profit margin?

Starling Oncology, Inc. (STLN) reported an operating income of $-36.1M, resulting in an operating profit margin of -7.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Starling Oncology, Inc.'s gross profit and gross margin?

Starling Oncology, Inc. (STLN) generated $76.4M in gross profit for the year, representing a gross profit margin of 15.2%. This demonstrates the company's core pricing power and production efficiency.